Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Cordis' Selution SLR DEB (sirolimus) drug-coated balloon for coronary in-stent restenosis under breakthrough designation
Small molecule, cardiovascular, drug-coated balloon, coronary in-stent restenosis, sirolimus, mTOR inhibitor - Read more

Roche's Gazyvaro (obinutuzumab) receives MHRA approval for systemic lupus erythematosus following Ph3 success
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, CD20, B cell depletion - Read more

AstraZeneca's Trixeo (budesonide/glycopyrronium/formoterol fumarate dihydrate) gains EU approval for asthma following Ph3 success
Small molecule, respiratory disease, combination therapy, asthma, inhaled corticosteroid, COPD - Read more

Novo Nordisk's Wegovy (semaglutide) wins Singapore approval for metabolic dysfunction-associated steatohepatitis with liver fibrosis based on Ph3 data
Small molecule, metabolic, GLP-1 receptor agonist, MASH, liver fibrosis, semaglutide - Read more

Boehringer Ingelheim expands Variant Bio cardiovascular collaboration, adding $250M in potential milestones
Research collaboration, cardiovascular, AI/ML, drug discovery, milestone payments - Read more

U.S. Department of War, Flagship Pioneering partner on medical countermeasures, $47M over five years
Government contract, infectious disease, AI/ML, vaccine, medical countermeasures - Read more

Cellares, Seoul National University Hospital partner to assess automated HSPC cell therapy manufacturing on Cell Shuttle platform
Manufacturing agreement, cell therapy, rare disease, gene therapy, automation - Read more

AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Apheris launch federated AI network AISB Bind for drug binding prediction
Research collaboration, AI/ML, small molecule, drug discovery, federated learning - Read more

Ligand Pharmaceuticals acquires royalty and milestone interest in Santen's Ryjunea from Sydnexis for $23M upfront
Licensing deal, ophthalmology, small molecule, royalties, milestone payments - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Roche, Ionis Pharmaceuticals' (sefaxersen) meets Ph3 endpoint in primary immunoglobulin A nephropathy, supporting accelerated approval bid
RNA therapy, kidney disease, antisense oligonucleotide, IgA nephropathy, proteinuria, accelerated approval - Read more

Caliway Biopharmaceuticals' (CBL-514) achieves second Ph2 win in Dercum's disease, delivering significant pain reduction
Small molecule, metabolic, injectable therapy, Dercum's disease, adipocyte apoptosis, lipoma - Read more

Anaconda Biomed raises $53M in funding to complete pivotal Athena endovascular trial
Neurovascular, medical device, stroke, endovascular, clinical-stage - Read more

Enveda raises $311M Series E crossover, advancing obesity and inflammatory disease candidates late-stage
AI/ML platform, small molecule, obesity, autoimmune, clinical-stage - Read more

Primrose Bio closes undisclosed funding round to expand biologics manufacturing technology portfolio
Biologics manufacturing, mRNA, vaccine production, CDMO, platform technology - Read more

CellsBin closes Series A, advancing Rare-Cell Biology platform for precision medicine
Rare-cell biology, AI/ML platform, cell therapy, biomarker discovery, hematologic cancers, precision medicine - Read more

Dialybrid raises €15M ($17.2M) Series A to fund clinical development of Silkothane hemodialysis vascular graft
Medical device, hemodialysis, vascular access, clinical-stage - Read more

Brandlin Ventures to acquire Celexir Inc., combining operations to advance peptide and stem cell wellness products
Stem cell therapy, aesthetics & wellness, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Immunovant's imeroprubart (IMVT-1402) fails Ph2b trial in cutaneous lupus erythematosus, anti-FcRn program continues elsewhere
Antibody, autoimmune, anti-FcRn, cutaneous lupus erythematosus, myasthenia gravis, Graves' disease - Read more

Bristol Myers Squibb cuts 265 more New Jersey jobs, bringing 2026 total layoffs to over 700
Restructuring, operational, cost reduction, financial - Read more

AstraZeneca, GSK, Roche, Novartis, Sanofi among nine pharma leaders urging EU policy reform to reverse biotech decline
Pharmaceutical industry, competitive, strategic, regulatory - Read more

Par Health recalls two IV sedative lots over cellulose, stopper contamination risks citing life-threatening effects
Small molecule, critical care, recall, operational, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here